Risk Factors Update Summary
- Addition of cash flows to risks affecting business, reputation, and stock price.
- Impairment loss of approximately $238.8 million recognized in the third quarter of 2023.
- Potential adverse effect of additional generic versions on business, with a further adverse effect.
- Impairment loss of approximately $36.0 million for INDOCIN and $4.8 million for Otrexup in Q4 2023.
- Risks associated with failure to successfully identify and acquire complementary businesses limiting growth.
- Any future impairments could materially adversely affect financial condition and results of operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1808665&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.